Evidence map›Paper›PMID 42769299›Full record

ArticleFrontiers in immunology2026

Early-onset CLL is characterized by enhanced microenvironment-driven metabolic fitness, increased proliferative bias, and accelerated disease progression.

Eugenia Payque, Santiago A Rodríguez-Zraquia, Marianela Lasagna, Rita Uria, Vanesa A Guazzone, Victoria Irigoin, Ana Inés Landoni, Victoria Remedi, Virginia Lema, Sabrina Ranero and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Eugenia Payque *Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Santiago A Rodríguez-Zraquia *Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Marianela LasagnaResearch Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Rita UriaResearch Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Vanesa A GuazzoneResearch Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Victoria IrigoinHematology Department, Centro de Asistencia del Sindicato Médico del Uruguay (CASMU), Montevideo, Uruguay.
Ana Inés LandoniHospital Maciel, ASSE, Montevideo, Uruguay.
Victoria RemediHospital Maciel, ASSE, Montevideo, Uruguay.
Virginia LemaHematology Department, Dirección Nacional de Sanidad de las Fuerzas Armadas, Montevideo, Uruguay.
Sabrina RaneroUnidad Académica de Hematología. Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Gabriela de GalvezHematology Department, Centro de Asistencia del Sindicato Médico del Uruguay (CASMU), Montevideo, Uruguay.
Raúl GabusHospital Maciel, ASSE, Montevideo, Uruguay.
Pablo MuxiHematology Department, Hospital Británico, Montevideo, Uruguay.
Helga Simon-MolasAmsterdam University Medical Centers (UMC) location University of Amsterdam, Experimental Immunology, and location Vrije Universiteit Amsterdam, Hematology, Amsterdam, Netherlands.
Carolina OliverHematology Department, Centro de Asistencia del Sindicato Médico del Uruguay (CASMU), Montevideo, Uruguay.
Pablo OppezzoResearch Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) predominantly affects older adults; however, approximately 10% of patients are diagnosed at a younger age. Although overall survival appears comparable across age groups, emerging evidence suggests that early-onset CLL may represent a biologically distinct disease subset. Given the profound effects of aging on immune competence and tumor-host interactions, we investigated whether age at diagnosis influences leukemic cell behavior, microenvironmental responsiveness, and immune dysfunction in CLL. We first analyzed the clinical impact of age at diagnosis in a Uruguayan cohort of 462 CLL patients and subsequently explored the biological basis underlying age-associated differences. Patients were stratified according to age at diagnosis, and disease progression was assessed by time-to-first treatment (TTFT). Metabolic analysis evaluated leukemic cell responses to prototypical tumor microenvironment (TME) stimuli, including CD40L plus IL-4 and CpG-ODN plus IL-15. In parallel, we characterized proliferative and quiescent leukemic fractions in peripheral blood, assessed T-cell exhaustion profiles, and analyzed metabolic reprogramming following microenvironmental stimulation. Patients diagnosed at ≤55 years of age exhibited the shortest TTFT (median 39 months), whereas those aged ≥65 years showed a significantly longer TTFT (median 97,6) confirming the more aggressive clinical course of early-onset CLL, despite the longer overall survival as previously described. Metabolic studies revealed that leukemic cells from younger patients displayed enhanced responsiveness to TME-derived signals, characterized by increased metabolic fitness and greater metabolic reprogramming following stimulation. Moreover, early-onset CLL was enriched in proliferative leukemic fractions, whereas the frequency and distribution of exhausted T-cell subsets were comparable between age groups. Collectively, our findings indicate that age-dependent differences in CLL behavior are primarily associated with intrinsic leukemic cell properties rather than major alterations in T-cell dysfunction. Early-onset CLL is characterized by enhanced metabolic adaptability and enrichment of proliferative leukemic cells, supporting the concept that it constitutes a biologically distinct subset of the disease. Despite the absence of differences in survival between age groups, our results provide new insights into CLL heterogeneity and suggest that age-related differences in leukemic cell-microenvironment interactions may contribute to the more aggressive clinical behavior observed in younger patients.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellTumor MicroenvironmentAdultAgedAged, 80 and overAge of OnsetCell ProliferationDisease ProgressionFemaleHumansMaleMetabolic ReprogrammingMiddle AgedT-Cell ExhaustionCENCATCLL - chronic lymphoblastic leukemiaearly-onsetmetabolic fitnesstumor micoenvironment

Identifiers

PMID42769299
PMCPMC13590693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.